InnerviewGI Workstation for Virtual Colonoscopy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

WESTBURY, New York-E-Z-Em, Inc. has begun marketing its InnerviewGI workstation for virtual colonoscopy procedures. The product is able to render three-dimensional (3D) images in just seconds and provides imaging professionals with multiple 3D view options (see figures below), as well as synchronized 2D and 3D views of the colon, the company said in a news release. InnerviewGI is powered by Vital Images’ Vitrea 2 software and features real-time navigation of 3D volume data.

WESTBURY, New York—E-Z-Em, Inc. has begun marketing its InnerviewGI workstation for virtual colonoscopy procedures. The product is able to render three-dimensional (3D) images in just seconds and provides imaging professionals with multiple 3D view options (see figures below), as well as synchronized 2D and 3D views of the colon, the company said in a news release. InnerviewGI is powered by Vital Images’ Vitrea 2 software and features real-time navigation of 3D volume data.

E-Z-Em also recently introduced PROTOCOL2L, its new colon insufflation system for virtual colonoscopy imaging procedures. The system consists of an automated insufflation device and disposable administration sets. The product uses carbon dioxide instead of room air to distend the colon for accurate imaging diagnosis and patient comfort. As an automated system, gas pressure is regulated and constant, minimizing the pressure spikes that can occur during manual insufflation, the company said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content